Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up – Here’s What Happened

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $13.95, but opened at $14.97. Bayer Aktiengesellschaft shares last traded at $14.95, with a volume of 160,871 shares trading hands.

Analysts Set New Price Targets

Separately, Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Check Out Our Latest Analysis on BAYRY

Bayer Aktiengesellschaft Stock Performance

The stock’s 50 day moving average price is $13.43 and its 200 day moving average price is $12.55. The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $58.75 billion, a price-to-earnings ratio of -29.31, a P/E/G ratio of 1.94 and a beta of 0.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02). Bayer Aktiengesellschaft had a positive return on equity of 16.77% and a negative net margin of 3.80%. Analysts expect that Bayer Aktiengesellschaft will post 1.27 earnings per share for the current year.

About Bayer Aktiengesellschaft

(Get Free Report)

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, hematology and specialty therapies.

Featured Stories

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.